Granted Patent
B2
US 12,252,549 · App. 17/304,909 · Granted Mar 18, 2025
Pertuzumab plus trastuzumab fixed dose combination
Inventors:
Tanja Badovinac-Crnjevic (Basel, CH); Yu Chien Fredriksson (Basel, CH); Sarah Heeson (Welwyn Garden, GB); Ihsan Hamdi Nijem (Brisbane, CA); Whitney Paige Kirschbrown (San Mateo, CA); Eleonora Restuccia (Basel, CH)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention disclosed concerns a fixed dose combination (FDC) of pertuzumab, trastuzumab, and, optionally, recombinant human hyaluronidase (rHuPH20), which is administered subcutaneously to patients. The final efficacy and safety data for the FeDeriCa clinical trial, United States Prescribing Information (USPI) (including home-use) methods, and primary analysis of the PHranceSCa clinical trial are disclosed and claimed.
Claims (16)
1. A method of treating HER2-positive early breast cancer patients comprising subcutaneously administering a therapeutically effective amount of a fixed dose combination (FDC) co-formulation of pertuzumab, trastuzumab, and hyaluronidase to said HER2-positive patients, said method comprising administering to said HER2-positive patients 8 cycles of neoadjuvant chemotherapy with concurrent administration of 4 cycles of said FDC during cycles 5 to 8, wherein:
(a) said neoadjuvant chemotherapy comprises:
(i) 4 cycles of 60 mg/m 2 doxorubicin and 600 mg/m 2 cyclophosphamide every 2 weeks followed by 80 mg/m 2 paclitaxel weekly for 12 weeks; or
(ii) 4 cycles of 60 mg/m 2 doxorubicin and 600 mg/m 2 cyclophosphamide every 3 weeks followed by 4 cycles of docetaxel at 75 mg/m 2 for the first cycle and then 100 mg/m 2 for subsequent cycles if tolerated every 3 weeks;
(b) said FDC is administered to said HER2-positive patients every 3 weeks for 4 cycles as a loading dose FDC comprising 1200 mg pertuzumab, 600 mg trastuzumab and 30,000 units of hyaluronidase, followed by maintenance dose FDC comprising 600 mg pertuzumab, 600 mg trastuzumab and 20,000 units of hyaluronidase; and
(c) said therapeutically effective amount causes a pathological complete response rate of about 60% or more in said HER2-positive patients; and
(d) said therapeutically effective amount results in ≤0.4% treatment-emergent neutralizing anti-pertuzumab antibodies in said HER2-positive patients.
2. The method of claim 1 , wherein said neoadjuvant chemotherapy comprises 4 cycles of 60 mg/m 2 doxorubicin and 600 mg/m 2 cyclophosphamide every 2 weeks followed by 80 mg/m 2 paclitaxel weekly for 12 weeks.
3. The method of claim 2 , wherein said therapeutically affective amount causes a pathological complete response rate of 66.7% in said HER2-positive patients.
4. The method of claim 1 , wherein said neoadjuvant chemotherapy comprises 4 cycles of 60 mg/m 2 doxorubicin and 600 mg/m 2 cyclophosphamide every 3 weeks followed by 4 cycles of docetaxel at 75 mg/m 2 for the first cycle and then 100 mg/m 2 for subsequent cycles if tolerated every 3 weeks.
5. The method of claim 1 , comprising administering maintenance dose FDC to said HER2-positive patients following surgery every 3 weeks for about 1 year (up to 18 cycles).
6. The method of claim 1 , wherein said HER2-positive patients have hormone receptor-negative cancer.
7. The method of claim 6 , wherein said therapeutically effective amount causes a pathological complete response rate of 70.8% in said HER2-positive patients.
8. The method of claim 1 , wherein said HER2-positive patients have stage II-IIIA cancer.
9. The method of claim 1 , wherein said HER2-positive patients have locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive).
10. The method of claim 1 , wherein said therapeutically effective amount results in an incidence of hypersensitivity≤1.2% in said HER2-positive patients.
Continuity (3)
Provisional Application
63065795
· Aug 14, 2020
Provisional Application
63045712
· Jun 29, 2020
References Cited (400)
US 4968603A
· Slamon et al.
· 1990
[cited by applicant]
US 5183884A
· Kraus et al.
· 1993
[cited by applicant]
US 5470954A
· Neslund et al.
· 1995
[cited by applicant]
US 5480968A
· Kraus et al.
· 1996
[cited by applicant]
US 5641869A
· Vandlen et al.
· 1997
[cited by applicant]
US 5648237A
· Carter
· 1997
[cited by applicant]
US 5677171A
· Hudziak et al.
· 1997
[cited by applicant]
US 5720937A
· Hudziak et al.
· 1998
[cited by applicant]
US 5720954A
· Hudziak et al.
· 1998
[cited by applicant]
US 5770195A
· Hudziak et al.
· 1998
[cited by applicant]
US 5772997A
· Hudziak et al.
· 1998
[cited by applicant]
US 5783186A
· Arakawa et al.
· 1998
[cited by applicant]
US 5725856A
· Hudziak et al.
· 1998
[cited by applicant]
US 5821337A
· Carter et al.
· 1998
[cited by applicant]
US 5824311A
· Greene et al.
· 1998
[cited by applicant]
US 6015567A
· Hudziak et al.
· 2000
[cited by applicant]
US 6127526A
· Blank et al.
· 2000
[cited by applicant]
US 6054297A
· Carter et al.
· 2000
[cited by applicant]
US 6165464A
· Hudziak et al.
· 2000
[cited by applicant]
US 6267958B1
· Andya et al.
· 2001
[cited by applicant]
US 6333169B1
· Hudziak et al.
· 2001
[cited by applicant]
US 6333398B1
· Blank
· 2001
[cited by applicant]
US 6339142B1
· Basey et al.
· 2002
[cited by applicant]
US 6489447B1
· Basey et al.
· 2002
[cited by applicant]
US 6399063B1
· Hudziak et al.
· 2002
[cited by applicant]
US 6387371B1
· Hudziak et al.
· 2002
[cited by applicant]
US 6407213B1
· Carter et al.
· 2002
[cited by applicant]
US 6417335B1
· Basey et al.
· 2002
[cited by applicant]
US 6573043B1
· Cohen et al.
· 2003
[cited by applicant]
US 6627196B1
· Baughman et al.
· 2003
[cited by applicant]
US 6632979B2
· Erickson et al.
· 2003
[cited by applicant]
US 6639055B1
· Carter et al.
· 2003
[cited by applicant]
US 6695940B2
· Devoe et al.
· 2004
[cited by applicant]
US 6685940B2
· Andya et al.
· 2004
[cited by applicant]
US 6719971B1
· Carter et al.
· 2004
[cited by applicant]
US 6800738B1
· Carter et al.
· 2004
[cited by applicant]
US 6797814B2
· Blank
· 2004
[cited by applicant]
US 6821151B2
· Lai et al.
· 2004
[cited by applicant]
US 6821515B1
· Cleland et al.
· 2004
[cited by applicant]
US 6905830B2
· Cohen et al.
· 2005
[cited by applicant]
US 6949245B1
· Sliwkowski et al.
· 2005
[cited by applicant]
US 7018809B1
· Carter
· 2006
[cited by applicant]
US 7060268B2
· Andya et al.
· 2006
[cited by applicant]
US 7097840B2
· Erickson et al.
· 2006
[cited by applicant]
US 7041292B1
· Sliwkowski
· 2006
[cited by applicant]
US 6984494B2
· Ralph
· 2006
[cited by applicant]
US 7074404B2
· Basey et al.
· 2006
[cited by applicant]
US 7279287B2
· Ralph
· 2007
[cited by applicant]
US 7344840B2
· Cohen et al.
· 2008
[cited by applicant]
US 7371376B1
· Fendly
· 2008
[cited by applicant]
US 7371379B2
· Baughman et al.
· 2008
[cited by applicant]
US 7435797B2
· Lowman et al.
· 2008
[cited by applicant]
US 7449184B2
· Allison et al.
· 2008
[cited by applicant]
US 7468252B2
· Cohen et al.
· 2008
[cited by applicant]
US 7485302B2
· Adams et al.
· 2009
[cited by applicant]
US 7485704B2
· Fahrner et al.
· 2009
[cited by applicant]
US 7498030B2
· Adams et al.
· 2009
[cited by applicant]
US 7537931B2
· Adams et al.
· 2009
[cited by applicant]
US 7560111B2
· Kao et al.
· 2009
[cited by applicant]
US 7575748B1
· Erickson et al.
· 2009
[cited by applicant]
US 7501122B2
· Adams et al.
· 2009
[cited by applicant]
US 7618631B2
· Sliwkowski
· 2009
[cited by applicant]
US 7531645B2
· Basey et al.
· 2009
[cited by applicant]
US 7682609B2
· Andya et al.
· 2010
[cited by applicant]
US 7700299B2
· Moecks et al.
· 2010
[cited by applicant]
US 7807799B2
· Fahrner et al.
· 2010
[cited by applicant]
US 7846441B1
· Hellmann
· 2010
[cited by applicant]
US 7674589B2
· Cohen et al.
· 2010
[cited by applicant]
US 7811773B2
· Ralph
· 2010
[cited by applicant]
US 7850966B2
· Lowman et al.
· 2010
[cited by applicant]
US 7879325B2
· Kao et al.
· 2011
[cited by applicant]
US 7892549B2
· Paton et al.
· 2011
[cited by applicant]
US 7862817B2
· Adams et al.
· 2011
[cited by applicant]
US 7993834B2
· Mass
· 2011
[cited by applicant]
US 8044017B2
· Emery et al.
· 2011
[cited by applicant]
US 8075890B2
· Carter et al.
· 2011
[cited by applicant]
US 8075892B2
· Hellmann
· 2011
[cited by applicant]
US 8076066B2
· Mass
· 2011
[cited by applicant]
US 8142784B2
· Ebens, Jr. et al.
· 2012
[cited by applicant]
US 8163287B2
· Sliwkowski et al.
· 2012
[cited by applicant]
US 8241630B2
· Kao et al.
· 2012
[cited by applicant]
US 8247397B2
· Belvin et al.
· 2012
[cited by applicant]
US 8309087B2
· Hellmann
· 2012
[cited by applicant]
US 8333964B2
· Agus et al.
· 2012
[cited by applicant]
US 8337856B2
· Blattler et al.
· 2012
[cited by applicant]
US 8404234B2
· Allison et al.
· 2013
[cited by applicant]
US 8597654B2
· Bryant
· 2013
[cited by applicant]
US 8425908B2
· Hellman
· 2013
[cited by applicant]
US 8440402B2
· Mass
· 2013
[cited by applicant]
US 8529901B2
· Hasmann et al.
· 2013
[cited by applicant]
US 8604014B2
· Belvin et al.
· 2013
[cited by applicant]
US 8591897B2
· Bryant
· 2013
[cited by applicant]
US 8592152B2
· Mass
· 2013
[cited by applicant]
US 8372396B2
· Andya et al.
· 2013
[cited by applicant]
US 8652474B2
· Harris et al.
· 2014
[cited by applicant]
US 8652479B2
· Ebens, Jr. et al.
· 2014
[cited by applicant]
US 8642036B2
· Hellmann
· 2014
[cited by applicant]
US 8663643B2
· Berry et al.
· 2014
[cited by applicant]
US 8710196B2
· Emery et al.
· 2014
[cited by applicant]
US 8758747B2
· Kallmeyer et al.
· 2014
[cited by applicant]
US 8691232B2
· Derynck et al.
· 2014
[cited by applicant]
US 8840896B2
· Lowman et al.
· 2014
[cited by applicant]
US 9017671B2
· Andya et al.
· 2015
[cited by applicant]
US 9181346B2
· Harris et al.
· 2015
[cited by applicant]
US 9345661B2
· Adler et al.
· 2016
[cited by applicant]
US 9551033B2
· Lee-Hoeflich et al.
· 2017
[cited by applicant]
US 9687568B2
· Hasmann et al.
· 2017
[cited by applicant]
US 9815904B2
· Gennaro et al.
· 2017
[cited by applicant]
US 9868760B2
· Emery et al.
· 2018
[cited by applicant]
US 9896478B2
· Lebreton et al.
· 2018
[cited by applicant]
US 9968676B2
· Adler et al.
· 2018
[cited by applicant]
US 9969811B2
· Gennaro et al.
· 2018
[cited by applicant]
US 20010014326A1
· Andya et al.
· 2001
[cited by applicant]
US 20020035736A1
· Erickson et al.
· 2002
[cited by applicant]
US 20020064785A1
· Mass
· 2002
[cited by applicant]
US 20030078388A1
· Basey et al.
· 2003
[cited by applicant]
US 20030134344A1
· Mass
· 2003
[cited by applicant]
US 20030147884A1
· Paton et al.
· 2003
[cited by applicant]
US 20030162796A1
· Hilberg et al.
· 2003
[cited by applicant]
US 20030170234A1
· Hellmann
· 2003
[cited by applicant]
US 20040106161A1
· Bossenmaier et al.
· 2004
[cited by applicant]
US 20040258685A1
· Brunetta et al.
· 2004
[cited by applicant]
US 20050025753A1
· Han et al.
· 2005
[cited by applicant]
US 20050244417A1
· Ashkenazi et al.
· 2005
[cited by applicant]
US 20050244929A1
· Carter
· 2005
[cited by applicant]
US 20050276812A1
· Ebens et al.
· 2005
[cited by applicant]
US 20060013819A1
· Kelsey
· 2006
[cited by applicant]
US 20060034840A1
· Agus
· 2006
[cited by applicant]
US 20060067930A1
· Adams et al.
· 2006
[cited by applicant]
US 20060083739A1
· Sliwkowski
· 2006
[cited by applicant]
US 20060088523A1
· Andya et al.
· 2006
[cited by applicant]
US 20060121044A1
· Amler et al.
· 2006
[cited by applicant]
US 20060188509A1
· Derynck et al.
· 2006
[cited by applicant]
US 20060204505A1
· Sliwkowski et al.
· 2006
[cited by applicant]
US 20060210561A1
· Baughman et al.
· 2006
[cited by applicant]
US 20060212956A1
· Crocker et al.
· 2006
[cited by applicant]
US 20060228745A1
· Mass
· 2006
[cited by applicant]
US 20070026001A1
· Ashkenazi et al.
· 2007
[cited by applicant]
US 20070184055A1
· Sliwkowski
· 2007
[cited by applicant]
US 20070202516A1
· Mass et al.
· 2007
[cited by applicant]
US 20070224203A1
· Friess et al.
· 2007
[cited by applicant]
US 20070009976A1
· Lenz et al.
· 2007
[cited by applicant]
US 20070269429A1
· Kelsey et al.
· 2007
[cited by applicant]
US 20080038271A1
· Amler et al.
· 2008
[cited by applicant]
US 20080050373A1
· Cohen
· 2008
[cited by applicant]
US 20080050385A1
· Friess et al.
· 2008
[cited by applicant]
US 20080241146A1
· Ashkenazi et al.
· 2008
[cited by applicant]
US 20080160026A1
· Ashkenazi et al.
· 2008
[cited by applicant]
US 20080102069A1
· Friess et al.
· 2008
[cited by applicant]
US 20080187533A1
· Hellmann
· 2008
[cited by applicant]
US 20080317753A1
· Amler et al.
· 2008
[cited by applicant]
US 20090087432A1
· Sliwkowski
· 2009
[cited by applicant]
US 20090220492A1
· Basey et al.
· 2009
[cited by applicant]
US 20090155259A1
· Derynck et al.
· 2009
[cited by applicant]
US 20090239236A1
· Mass
· 2009
[cited by applicant]
US 20090226455A1
· Filvaroff
· 2009
[cited by applicant]
US 20090148401A1
· Mrsny
· 2009
[cited by applicant]
US 20090148402A1
· Brunetta et al.
· 2009
[cited by applicant]
US 20090148435A1
· Lebreton et al.
· 2009
[cited by applicant]
US 20090317387A1
· Paton et al.
· 2009
[cited by applicant]
US 20100196363A1
· Vanhauwere et al.
· 2010
[cited by applicant]
US 20100112603A1
· Moecks et al.
· 2010
[cited by applicant]
US 20100158899A1
· Andya et al.
· 2010
[cited by applicant]
US 20100285010A1
· Friess et al.
· 2010
[cited by applicant]
US 20100298156A1
· Lee-Hoeflich et al.
· 2010
[cited by applicant]
US 20110129464A1
· Adams et al.
· 2011
[cited by applicant]
US 20110117096A1
· Bossenmaier et al.
· 2011
[cited by applicant]
US 20110245103A1
· Amler et al.
· 2011
[cited by applicant]
US 20110246399A1
· Amler et al.
· 2011
[cited by applicant]
US 20110223159A1
· Friess et al.
· 2011
[cited by applicant]
US 20110236383A1
· Andya et al.
· 2011
[cited by applicant]
US 20110033460A1
· Fendly et al.
· 2011
[cited by applicant]
US 20120107391A1
· Kelsey
· 2012
[cited by applicant]
US 20120251530A1
· Sliwkowski et al.
· 2012
[cited by applicant]
US 20120121586A1
· Kiermaier et al.
· 2012
[cited by applicant]
US 20130195845A1
· Fendly et al.
· 2013
[cited by applicant]
US 20130195851A1
· Alavattam et al.
· 2013
[cited by applicant]
US 20130108620A1
· Blattler et al.
· 2013
[cited by applicant]
US 20130095172A1
· Alavattam et al.
· 2013
[cited by applicant]
US 20130142865A1
· Allison et al.
· 2013
[cited by applicant]
US 20130149299A1
· Baughman et al.
· 2013
[cited by applicant]
US 20130183292A1
· Friess et al.
· 2013
[cited by applicant]
US 20130209459A1
· Hellmann
· 2013
[cited by applicant]
US 20130216532A1
· Adler et al.
· 2013
[cited by applicant]
US 20130345217A1
· Belvin et al.
· 2013
[cited by applicant]
US 20140044704A1
· Paton et al.
· 2014
[cited by applicant]
US 20140044709A1
· Klencke et al.
· 2014
[cited by applicant]
US 20140086940A1
· Bryant
· 2014
[cited by applicant]
US 20140093458A1
· Dobosz et al.
· 2014
[cited by applicant]
US 20140186347A1
· Derynck et al.
· 2014
[cited by applicant]
US 20140186867A1
· Harris et al.
· 2014
[cited by applicant]
US 20140248274A1
· Kallmeyer et al.
· 2014
[cited by applicant]
US 20140248609A1
· Mass
· 2014
[cited by applicant]
US 20140140993A1
· Ross et al.
· 2014
[cited by applicant]
US 20140212411A1
· Blattler et al.
· 2014
[cited by applicant]
US 20140128580A1
· Ebens, Jr. et al.
· 2014
[cited by applicant]
US 20140322202A1
· Cohen
· 2014
[cited by applicant]
US 20140341886A1
· Hellmann
· 2014
[cited by applicant]
US 20160175438A1
· Alavattam et al.
· 2016
[cited by applicant]
US 20160376377A1
· Basey et al.
· 2016
[cited by applicant]
US 20170136026A1
· Sliwkowski et al.
· 2017
[cited by applicant]
US 20170166656A1
· Lowman et al.
· 2017
[cited by applicant]
US 20170174785A1
· Harris et al.
· 2017
[cited by applicant]
US 20170190786A1
· Fendly et al.
· 2017
[cited by applicant]
US 20170035907A1
· Green et al.
· 2017
[cited by applicant]
US 20170037147A1
· Allison et al.
· 2017
[cited by applicant]
US 20170008971A1
· Dennis et al.
· 2017
[cited by applicant]
US 20180118781A1
· Lebreton et al.
· 2018
[cited by applicant]
US 20180280408A1
· Belvin et al.
· 2018
[cited by applicant]
US 20180282428A1
· Fendly et al.
· 2018
[cited by applicant]
US 20180134803A1
· Douthwaite et al.
· 2018
[cited by applicant]
US 20180162951A1
· Cohen
· 2018
[cited by applicant]
US 20180251557A1
· Chui et al.
· 2018
[cited by applicant]
US 20180201692A1
· Lowman et al.
· 2018
[cited by applicant]
US 20180037661A1
· Gennaro et al.
· 2018
[cited by applicant]
US 20180037662A1
· Gennaro et al.
· 2018
[cited by applicant]
US 20180228895A1
· Adler et al.
· 2018
[cited by applicant]
US 20180236072A1
· Derynck et al.
· 2018
[cited by applicant]
US 20180236093A1
· Bryant
· 2018
[cited by applicant]
US 20180221481A1
· Beattie et al.
· 2018
[cited by applicant]
US 20180221488A1
· Andya et al.
· 2018
[cited by applicant]
US 20180274038A1
· Belousov et al.
· 2018
[cited by applicant]
US 20180327510A1
· Allison et al.
· 2018
[cited by applicant]
US 20190055317A1
· Baughman et al.
· 2019
[cited by applicant]
US 20190117769A1
· Benyunes et al.
· 2019
[cited by applicant]
US 20190145985A1
· Zemo
· 2019
[cited by examiner]
US 20190070291A1
· Mass
· 2019
[cited by applicant]
US 20190240185A1
· Desmond-Hellman et al.
· 2019
[cited by applicant]
US 20200206348A1
· Benyunes et al.
· 2020
[cited by applicant]
US 20200172631A1
· Seshagiri et al.
· 2020
[cited by applicant]
US 20200157208A1
· Barrington
· 2020
[cited by examiner]
US 20200157238A1
· Gennaro et al.
· 2020
[cited by applicant]
US 20200237910A1
· Beattie et al.
· 2020
[cited by applicant]
US 20200239595A1
· Allison et al.
· 2020
[cited by applicant]
US 20200179515A1
· Andya et al.
· 2020
[cited by applicant]
US 20210085597A1
· Eng-Wong et al.
· 2021
[cited by applicant]
US 20220362379A1
· Benyunes et al.
· 2022
[cited by applicant]
US 20230212311A1
· Allison et al.
· 2023
[cited by applicant]
US 20230250187A1
· Paton et al.
· 2023
[cited by applicant]
US 20230263895A1
· Andya et al.
· 2023
[cited by applicant]
US 20230277664A1
· Ross et al.
· 2023
[cited by applicant]
US 20230310455A1
· Schutzman et al.
· 2023
[cited by applicant]
US 20230314420A1
· Avenal et al.
· 2023
[cited by applicant]
US 20230416401A1
· Harris et al.
· 2023
[cited by applicant]
US 20240269064A1
· Eng-Wong et al.
· 2024
[cited by applicant]
EP 3570884B1
· 2020
[cited by applicant]
WO 9704801A1
· 1997
[cited by applicant]
WO 9931140A1
· 1999
[cited by applicant]
WO 0189566A1
· 2001
[cited by applicant]
WO 2004078140A2
· 2004
[cited by applicant]
WO 2006044908A2
· 2006
[cited by applicant]
WO 2006078307A1
· 2006
[cited by applicant]
WO 2006091871A1
· 2006
[cited by applicant]
WO 2008031531A1
· 2008
[cited by applicant]
WO 2011012637A2
· 2011
[cited by applicant]
WO 2011012637A3
· 2011
[cited by applicant]
WO 2011012637A4
· 2011
[cited by applicant]
WO 2011069074A2
· 2011
[cited by applicant]
WO 2016044334A1
· 2016
[cited by applicant]
WO 2016044396A1
· 2016
[cited by applicant]
WO 2018136412A2
· 2018
[cited by applicant]
WO WO2019175125A1
· 2019
[cited by examiner]
WO 2023178019A1
· 2023
[cited by applicant]
Diaz-Redondo et al (Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: A…
[cited by examiner]
Agus, D., et al., “Clinical Activity in a Phase I Trial of HER-2-Targeted rhuMAb 2C4 (pertuzumab) in Patients with Advanced Solid Malignancies (AST)” Proceedings of the American Society of Clinical Oncology (Abstract No…
[cited by applicant]
Agus, D., et al., “Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer” J Clin Oncol 23(11):2534-2543 (Apr. 10, 2005).
[cited by applicant]
Agus, D., et al., “Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth” Cancer Cell 2(2):127-137 (Aug. 1, 2002).
[cited by applicant]
Allison, D., et al., “Pharmacokinetics of HER2-targeted rhuMAb 2C4 (pertuzumab) in patients with advanced solid malignancies: Phase Ia results” Pro Am Soc Clin Oncol 22:197 (Jun. 3, 2003).
[cited by applicant]
Arming, S. et al., “In vitro Mutagenesis of PH-20 Hyaluronidase from Human Sperm” Eur J Biochem 247(3):810-814 (Aug. 1, 1997).
[cited by applicant]
Arthur, A., “Innovations in subcutaneous infusions” J Infus Nurs 38(3):179-187 (May 31, 2015).
[cited by applicant]
Assouline, S., et al., “Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia” Br J Clin Pharmacol 80(5):1001-1009 (Nov. 1, 2015).
[cited by applicant]
Aulton, M. Aulton's Pharmaceutics—The Design and Manufacture of Medicines “Excerpt pp. 317-319” Third edition,Churchill Livingstone,: 1-5 (Jan. 1, 2007).
[cited by applicant]
Baselga, J., et al., “Objective response rate in a phase II multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positi…
[cited by applicant]
Baselga, J., et al., “Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer” N Engl J Med 366(2):109-119 (Jan. 12, 2012).
[cited by applicant]
Baselga, J., et al., “Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer” J Clin Oncol 14(3):737-744 (Mar. 1, 1…
[cited by applicant]
BC Cancer Drug Agency et al., “BC Cancer Agency Cancer Drug Manual” (Drug Name: Pertuzumab; Common Trade Name(s): PERJETA),:1-6 (Jan. 1, 2014).
[cited by applicant]
Beaute, J., et al., “Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies” Clin Exp Immunol 160(2):240-245 (May 1, 2010).
[cited by applicant]
Berger, M., et al., “Bioavailability of IgG Administered by the Subcutaneous Route” J Clin Immunol 33(5):984-990 (Mar. 1, 2013).
[cited by applicant]
Bittner, B., et al., “Development of a subcutaneous formulation for trastuzumab—nonclinical and clinical bridging approach to the approved intravenous dosing regimen” ARZNEIMITTELFORSCHUNG 62(9):401-409 (Sep. 1, 2012).
[cited by applicant]
Bittner, B., et al., “Non-Clinical Pharmacokinetic/Pharmacodynamic and Early Clinical Studies Supporting Development a Novel Subcutaneous Formulation for the Monoclonal Antibody Rituximab” Drug Res (Stuttg). 64(11):569-…
[cited by applicant]
Bookbinder, L.H., et al., “A recombinant human enzyme for enhanced interstitial transport of therapeutics” J Control Release 114(2):230-241 (Aug. 28, 2006).
[cited by applicant]
Bywaters, E. G. L. et al., “Reconstitution of the Dermal Barrier to Dye Spread After Hyaluronidase Injection” Brit Med J 2(4741):1178-1183 (Nov. 17, 1951).
[cited by applicant]
Carpenter, J.F., et al. Rational Design of Stable Protein Formulations, Theory and Practice “Excerpt pp. 66, 187-188” New York:Kluwer Academic/Plenum Publishers,:7 ( 2002).
[cited by applicant]
Celltrion Press Release, “Remsima SC joins the existing market for subcutaneous injections . . . signaling a drastic change in autoimmune treatments” MoneyToday-Korea (Interview, CEO—SEO, Jung-Jin; Korean with Eng. Tran…
[cited by applicant]
Chain, E., et al., “A Mucolytic Enzyme in Testes Extracts” Nature 144(3658):977-978 (Dec. 9, 1939).
[cited by applicant]
Cherr, G. N. et al., “The PH-20 Protein in Cynomolgus Macaque Spermatozoa: Identification of Two Different Forms Exhibiting Hyaluronidase Activity” Dev Biol 175(1):142-153 (Apr. 10, 1996).
[cited by applicant]
Cherry, R.S., et al., “Physical Mechanisms of Cell Damage in Microcarrier Cell Culture Bioreactors” Biotechnol Bioeng 32(8):1001-1014 (Oct. 5, 1988).
[cited by applicant]
Cho, H.S., et al., “Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab” Nature 421(6924):756-760 (Feb. 13, 2003).
[cited by applicant]
Clinicaltrials.gov, “A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Early Breast Cancer (EBC)” (History of Changes for Study: NCT02738970; Submitted date: Jul. 1, 2016 (v4); …
[cited by applicant]
ClinicalTrials.gov, “A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)” (History of Changes for Study: NCT0273…
[cited by applicant]
ClinicalTrials.gov, “A Study of Pertuzumab and Trastuzumab Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-positive Metastatic Breast Cancer ” (History of Chan…
[cited by applicant]
Clinicaltrials.gov, “A Study of Pertuzumab and Trastuzumab Treatment in Combination with a Taxane in Participants with Human Epidermal Growth Factor Receptor 2 (HER2)-positive Metastatic Breast Cancer” (History of Chang…
[cited by applicant]
ClinicalTrials.gov, “A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer” (History of Changes for NCT00545688; first posted: Oct. 17, 2007; Submitted Date: Nov. 1, 2016 (v120…
[cited by applicant]
ClinicalTrials.gov, “Phase Illb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer” (History of Changes for Study: NCT02402712;…
[cited by applicant]
ClinicalTrials.gov, “A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY)” (Clinic…
[cited by applicant]
ClinicalTrials.gov, “A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer” (Cli…
[cited by applicant]
ClinicalTrials.gov., A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer (Cleopatra) (ClinicalTrials.gov Identifi…
[cited by applicant]
Cortes, J., et al., “Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Po…
[cited by applicant]
Danilkovitch-Miagkova, A. et al., “Hyaluronidase 2 Negatively Regulates RON Receptor Tyrosine Kinase and Mediates Transformation of Epithelial Cells by Jaagsiekte Sheep Retrovirus” PNAS USA 100(8):4580-4585 (Apr. 15, 20…
[cited by applicant]
Davies, A., et al., “Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (Sabrina): stage 1 analysis of a randomised phase 3 study” Lancet Oncol 15(3):343-352 (Mar. 1, 2014).
[cited by applicant]
De Cock, E., et al., “A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer” Cancer Med 5(3):389-397 (Mar. 1, 2016).
[cited by applicant]
Denys, H., et al., “Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer” Breast Cancer Res Treat 181(1):97-10…
[cited by applicant]
Duran-Reynals, F.,, “A spreading factor in certain snake venoms and its relation to their mode of action” J Exp Med 69(1):69-81 (Jan. 1, 1938).
[cited by applicant]
European Medicines Agency, “Assessment Report—Perjeta (Pertuzumab) Procedure No. EMEA/H/C/002547/000” Committee for Medicinal Products for Human Use EMA/17250/2013(Rev. 04.12):1-123 (Dec. 13, 2012).
[cited by applicant]
European Medicines Agency, “CHMP Assessment Report, Herceptin (trastuzumab) Procedure No. EMEA/H/C/000278” Committee for Medicinal Products for Human Use EMA/CHMP/751770/2012/CORR1:1-70 (Jun. 27, 2013).
[cited by applicant]
European Medicines Agency, “Herceptin—Procedural Steps Taken and Scientific Information After the Authorisation” EMA/216822/2021:excerpt, pp. 1-3 ( 2021).
[cited by applicant]
Friess, T., et al., “Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy” Clin Cancer Res 11(14):5300-5309 (Jul. 15, 2005).
[cited by applicant]
Frost, G. I. et al., “A microtiter-based assay for hyaluronidase activity not requiring specialized reagents” Anal Biochem 251(2):263-269 (Sep. 5, 1997).
[cited by applicant]
Frost, G. I. et al., “Purification, Cloning, and Expression of Human Plasma Hyaluronidase” Biochem Bioph Res Co 236(1):10-15 (Jul. 9, 1997).
[cited by applicant]
Frost, G. I.,, “Recombinant Human Hyaluronidase (rHuPH20): an Enabling Platform for Subcutaneous Drug and Fluid Administration” Expert Opin Drug Del 4(4):427-440 (Jul. 1, 2007).
[cited by applicant]
Cited By (3)